| |
The pharmacological properties of IDX19368, a novel nucleotide prodrug, highlight its potential for use in a low-dose DAA regimen for HCV
|
| |
| |
Reported by Jules Levin
Presented at the XXth IRT - 05-09th Aug. 2012 - Montreal, Canada
C.B. Dousson*, C. Parsy, K. Gupta, B. Hernandez-Santiago, J.-L. Paparin, C. Pierra, D. Dukhan, A. Roland, M. La Colla, N. Golitsina, M. Seifer, G. Gosselin & D. Surleraux
Idenix Pharmaceuticals, Inc., Cambridge, MA, USA and Montpellier, France
|
|
| |
| |
|
|
|
